Implant Sciences' Quantum Sniffer QS-B220 Bench-Top Explosives Trace Detector Achieves ASTM E2520 Certification

Standard Establishes Effectiveness of QS-B220 for Security Screeners and First Responders

Marketwired

WILMINGTON, MA--(Marketwire -02/06/12)- Implant Sciences Corporation (OTCQB: IMSC.PK - News) (Pinksheets: IMSC.PK - News), a high technology supplier of systems and sensors for homeland security markets, announced today that its Quantum Sniffer™ QS-B220 bench-top explosives trace detector has passed all tests of the ASTM E2520-07 "Standard Practice for Verifying Minimum Acceptable Performance of Trace Explosive Detectors." The test confirms that the QS-B220 performs to the required standards of performance in the detection of trace amounts of explosives including TNT, RDX, and PETN. The tests were conducted by Cambridge Polymer Group, an independent laboratory. ASTM International, formerly known as the American Society for Testing and Materials (ASTM), is a globally recognized leader in the development and delivery of international voluntary consensus standards.

"The QS-B220's validation through this test brings it another step closer to commercial adoption in the US. Non-TSA security screeners and first responders can now purchase and deploy our bench-top explosives and narcotics trace detector in complete confidence that it is an effective technology," stated Glenn D. Bolduc, President and CEO of Implant Sciences. "We are confident in the performance of our QS-B220 and anticipate that this is the first of many detection standards around the world to which it will be successfully certified."

The QS-B220 had been engineered to meet the needs of a wide range of security applications. It has recently received CE Certification and is being evaluated by security organizations around the world.

About the Quantum Sniffer™ QS-H150

The QS-H150 is a handheld explosives trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. The QS-H150 uses no radioactive materials and features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About the Quantum Sniffer™ QS-B220

The QS-B220, introduced in May 2011, is a bench-top explosives and narcotics trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives, plus narcotic substances. The QS-B220 continues the Implant Sciences tradition of freedom from radioactive materials, low total cost of ownership, and high operational availability.

About Implant Sciences

Implant Sciences develops, manufactures, and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed innovative proprietary technologies used in its explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences products have been deployed in a wide range of security environments including airports, subways, railways, cargo facilities, nuclear power plants, police departments, military units, government buildings, and financial institutions. The QS-H150 and QS-B220 are Department of Homeland Security (DHS) Qualified Anti-Terrorism Technologies under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact
or
Investor
Laurel Moody
646-810-0608
Email Contact

View Comments (0)